Tissue sections were then incubated with anti-ALK antibody (clone D5F3, VMSI) for 20 minutes

Tissue sections were then incubated with anti-ALK antibody (clone D5F3, VMSI) for 20 minutes. international collaborators. These specimens CCG-1423 were stained by IHC with the anti-ALK (D5F3) primary antibody combined with OptiView DAB IHC detection and OptiView amplification (Ventana Medical Systems, Inc., Tucson, AZ). Specimens were scored binarily as positive if strong granular cytoplasmic brown staining was present in tumor cells. IHC results were compared with the FISH results and interevaluator comparisons made. Results Overall for the 100 evaluable cases the ALK IHC assay was highly sensitive (90%), specific (95%), and accurate relative (93%) to the FISH results. Similar results were observed using a majority score. IHC negativity was scored by seven of seven and six of seven evaluators on three and two FISH-positive cases, respectively. IHC positivity was scored on two FISH-negative cases by seven of seven readers. There was agreement among seven of seven and six of seven readers on 88% and 96% of the cases before review, respectively, and after review there was agreement among seven of seven and six of seven on 95% and 97% of the cases, respectively. Conclusions On the basis of expert evaluation the ALK IHC test is sensitive, specific, and accurate, and a majority score of multiple readers does not improve these results over an individual readers score. Excellent inter-reader agreement was observed. These data support the algorithmic use of ALK IHC in the evaluation of NSCLC. Keywords: NonCsmall-cell lung cancer, Anaplastic Rabbit polyclonal to ZNHIT1.ZNHIT1 (zinc finger, HIT-type containing 1), also known as CG1I (cyclin-G1-binding protein 1),p18 hamlet or ZNFN4A1 (zinc finger protein subfamily 4A member 1), is a 154 amino acid proteinthat plays a role in the induction of p53-mediated apoptosis. A member of the ZNHIT1 family,ZNHIT1 contains one HIT-type zinc finger and interacts with p38. ZNHIT1 undergoespost-translational phosphorylation and is encoded by a gene that maps to human chromosome 7,which houses over 1,000 genes and comprises nearly 5% of the human genome. Chromosome 7 hasbeen linked to Osteogenesis imperfecta, Pendred syndrome, Lissencephaly, Citrullinemia andShwachman-Diamond syndrome. The deletion of a portion of the q arm of chromosome 7 isassociated with Williams-Beuren syndrome, a condition characterized by mild mental retardation, anunusual comfort and friendliness with strangers and an elfin appearance lymphoma kinase, Immunohistochemistry, Fluorescence in situ hybridization, Companion diagnostics, Biomarkers, Crizotinib Personalized medicine is at the forefront of lung cancer therapy with the goal to reduce CCG-1423 the 1.4 million lung cancer deaths per year worldwide.1 The fundamental principal of personalized medicine is treating patients with a therapy predicted to be efficacious based on the molecular characteristics of the tumor, thereby sparing the patient any potential morbidity and mortality associated with ineffective therapy. NonCsmall-cell lung cancer (NSCLC) accounts for 85% of all lung cancer and the 5-year survival rate for NSCLC is only 16% because of late-stage diagnosis2 and lack of effective systemic therapy. However, treatment for advanced disease has improved recently commensurate with the identification of key oncogenic alternations driving tumorigenesis, such as activating somatic mutations or chromosomal rearrangements targetable with specific therapeutics. 3 Tumors harboring epidermal growth factor receptor mutations are distinctly sensitive to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) like erlotinib and gefitinib,4C8 whereas tumors containing anaplastic lymphoma kinase (gene rearrangements were first discovered in NSCLC in 2007 by Soda et al.11 who identified that the 3 end of was juxtaposed to the 5 end of echinoderm microtubule- associated protein-like 4 (gene rearrangements is approximately 3% to 4% in an unselected NSCLC population, which equates to roughly 40,000 ALK- positive patients/year worldwide.1,17 NSCLC tumors that contain rearrangement are strikingly responsive to the ALK TKI crizotinib (PF-02341066, Xalkori; Pfizer, New York, NY), an adenosine triphosphate (ATP) competitive small- molecule targeting the kinase domain in the ALK protein.18 An international multicenter phase I study initially demonstrated an objective response rate of 60.8% and a disease control rate of 84% among the 143 evaluable patients.9,10 The median duration of response was 49.1 weeks and the median progression-free survival (PFS) was 9.7 months for all, often heavily pretreated patients, but a PFS of 18.3 months was observed for those receiving crizotinib as first-line therapy. The estimated overall survival at 6 and 12 months was 87.9% and 74.8%, but these data are not fully mature. Interim results of an ongoing phase 2 study have shown an overall response rate of 53% and a median PFS of 8.5 months.19 Early results from a phase III study (PROFILE 1007) comparing chemotherapy with crizotinib revealed an increase in PFS from a median of 3.0 months to 7.7 months and an overall response rate of 20% versus 65%.20 Numerous other phase III clinical trials are CCG-1423 ongoing. Crizotinib received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2011, but approval was contingent upon documentation of ALK positivity by an FDA-approved diagnostic test, and to date the only FDA-approved companion diagnostic is the fluorescence in situ hybridization (FISH) assay using the Vysis break-apart FISH probe kit (Abbott Molecular, Des Plaines, IL).21 Numerous studies indicate that immunohistochemistry (IHC), under the appropriate conditions, is sensitive and specific for determination of ALK protein expression22C28 and is a practical cost-effective alternative to the FISH assay. In fact, there are even potential clinical benefits to ALK IHC over FISH, as demonstrated by significant clinical improvement from crizotinib.